dc.contributor.author | Bonaccorso, Stefania | |
dc.contributor.author | Ricciardi, Angelo | |
dc.contributor.author | Ouabbou, Sophie | |
dc.contributor.author | Theleritis, Christos | |
dc.contributor.author | Ross-Michealides, Arabella | |
dc.contributor.author | Metastasio, Antonio | |
dc.contributor.author | Stewart, Neil | |
dc.contributor.author | Mohammed, Marwa | |
dc.contributor.author | Schifano, Fabrizio | |
dc.date.accessioned | 2021-02-26T14:41:43Z | |
dc.date.available | 2021-02-26T14:41:43Z | |
dc.date.issued | 2021-05 | |
dc.identifier.citation | Bonaccorso , S , Ricciardi , A , Ouabbou , S , Theleritis , C , Ross-Michealides , A , Metastasio , A , Stewart , N , Mohammed , M & Schifano , F 2021 , ' Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report ' , Brain Behavior and Immunity , vol. 13 , 100212 . https://doi.org/10.1016/j.bbih.2021.100212 | |
dc.identifier.issn | 0889-1591 | |
dc.identifier.uri | http://hdl.handle.net/2299/23951 | |
dc.description | © 2021 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | |
dc.description.abstract | Background: Clozapine is among the most effective antipsychotics used for treatment resistant schizophrenia. Adverse reactions to clozapine include neutropenia. In March 2020, at the start of the Coronavirus -19 pandemic, clinicians raised concerns regarding continuation of antipsychotic treatment, and specifically of clozapine, in patients with coronavirus disease. We aimed here at providing a short report focusing on the association between neutropenia and clozapine in a case series of psychiatric inpatients diagnosed with COVID-19.Patients & methods: We retrospectively inspected data of 10 patients on clozapine, admitted to Highgate Mental Health Centre, Camden & Islington NHS Foundation Trust, between March and July 2020; selection was based on their COVID-19 positive PCR test. We used a linear regression model to estimate whether there was a significant drop in the neutrophil count during SARS-CoV-2 infection.The analysis was done in R using a linear regression to the origin.Results: Data were collected on 10 patients, of which 7 were males. During COVID-19 infection, neutrophils' count (ANC) was 4.13 × 10 9/l (SD = 2.70) which constituted a significant drop from a baseline value of 5.2 × 10 9/l (SD = 2.24). The mean relative reduction in ANC was -0.2729 (SD = 0.1666). The beta value of 0.8377 obtained with the linear regression showed that ANC values during SARS-CoV-2 infection were 83.77% of the baseline ANC showing that within the two time points there was a decrease of 16.23%. The linear regression had a pvalue = 8.96 × 10 -8 and an adjusted R 2 of 95.94% which shows that the variability of the data is very well explained by the model. We also compared baseline ANC with ANC values approximately a month after resolution of the infection and results indicate that ANC values return to a 95% of baseline. Conclusions: Clinicians should bear in mind that a significant drop in neutrophils' count may occur in patients taking clozapine and affected from a SARS-CoV-2 infectionand that this drop is only transitory. | en |
dc.format.extent | 4 | |
dc.format.extent | 294400 | |
dc.language.iso | eng | |
dc.relation.ispartof | Brain Behavior and Immunity | |
dc.subject | Clozapine | |
dc.subject | Coronavirus | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.subject | Psychosis | |
dc.subject | Schizophrenia | |
dc.subject | Lymphopenia | |
dc.subject | Agranulocytosis | |
dc.subject | Neutrophils | |
dc.subject | Neutropenia | |
dc.subject | Neutrophilia | |
dc.subject | absolute neutrophil count (ANC) | |
dc.title | Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report | en |
dc.contributor.institution | Centre for Health Services and Clinical Research | |
dc.contributor.institution | Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit | |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.description.status | Peer reviewed | |
rioxxterms.versionofrecord | 10.1016/j.bbih.2021.100212 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |